Apogee Therapeutics Reports Strong Cash Position and Advances Key Clinical Programs Towards Phase 3

summarizeSummary

Apogee Therapeutics announced robust full year 2025 financial results, highlighted by a substantial cash position of $902.9 million, which provides a runway into the second half of 2028. This significantly de-risks the company from near-term financing concerns. Concurrently, the company provided critical updates on its clinical pipeline, including the anticipated Phase 2 data readouts for zumilokibart (APG777) in atopic dermatitis this quarter and next, with plans to initiate a Phase 3 trial in the second half of 2026. The successful Phase 1b trial in asthma further demonstrates the potential for pipeline expansion, and the ongoing head-to-head trial against DUPIXENT for APG279 offers a significant future catalyst. These advancements, coupled with a strong balance sheet, position the company favorably for continued development and potential commercialization.

check_boxKey Events

• Strong Cash Position and Extended Runway

  The company reported cash, cash equivalents, and marketable securities of $902.9 million as of December 31, 2025, up from $731.1 million in 2024. This capital is expected to fund operations into the second half of 2028, significantly reducing near-term financing risk.

• Zumilokibart (APG777) Advancing to Phase 3

  Key data readouts for zumilokibart in atopic dermatitis are expected soon: APEX Phase 2 Part A 52-week data this month (March 2026) and APEX Phase 2 Part B 16-week data in Q2 2026. The company plans to initiate a Phase 3 trial in AD in the second half of 2026.

• Pipeline Expansion into Asthma and EoE

  Zumilokibart demonstrated positive interim results from a Phase 1b trial in mild-to-moderate asthma, reinforcing its potential across inflammatory and immunology indications. Further details on asthma and eosinophilic esophagitis (EoE) trials are expected later this year.

• Head-to-Head Trial vs. DUPIXENT Underway

  A Phase 1b head-to-head study of APG279 (zumilokibart + APG990) against DUPIXENT in atopic dermatitis is progressing, with interim data anticipated in the second half of 2026.

auto_awesomeAnalysis

Apogee Therapeutics announced robust full year 2025 financial results, highlighted by a substantial cash position of $902.9 million, which provides a runway into the second half of 2028. This significantly de-risks the company from near-term financing concerns. Concurrently, the company provided critical updates on its clinical pipeline, including the anticipated Phase 2 data readouts for zumilokibart (APG777) in atopic dermatitis this quarter and next, with plans to initiate a Phase 3 trial in the second half of 2026. The successful Phase 1b trial in asthma further demonstrates the potential for pipeline expansion, and the ongoing head-to-head trial against DUPIXENT for APG279 offers a significant future catalyst. These advancements, coupled with a strong balance sheet, position the company favorably for continued development and potential commercialization.